Alveolar Soft Part Sarcoma (ASPS) — What You Need to Know

What Is Alveolar Soft Part Sarcoma?

Alveolar soft part sarcoma (ASPS) is a rare malignant tumour of uncertain cellular origin — most evidence now suggests it arises from cells of skeletal muscle lineage, though this has not been definitively resolved. What makes ASPS unique among soft tissue sarcomas is its molecular fingerprint: virtually every case is driven by a characteristic chromosomal translocation, der(17)t(X;17)(p11;q25), which fuses the ASPSCR1 gene (formerly ASPL) to the TFE3 transcription factor gene. The resulting ASPSCR1–TFE3 fusion protein drives uncontrolled proliferation and angiogenesis, explaining why ASPS is one of the most vascular tumours in oncology — and why anti-angiogenic targeted therapy has emerged as its most effective systemic treatment.

On pathology, the tumour has a distinctive "alveolar" architecture: nests of large, polygonal cells separated by thin fibrovascular septa, giving the false impression of an organ with air spaces — hence the name. The cells contain periodic acid-Schiff (PAS)-positive, diastase-resistant crystalline inclusions, which are highly characteristic and aid diagnosis. ASPS accounts for roughly 0.5–1% of all soft tissue sarcomas, with an estimated incidence of fewer than 300 new cases per year in India. It is equally rare in Telangana and Hyderabad, making a specialist multidisciplinary tumour board critical for any patient who receives this diagnosis. For context on where ASPS fits in the broader landscape, see the sarcoma overview hub.

Who Gets ASPS and Where Does It Arise?

ASPS has a striking predilection for children, teenagers, and young adults. The median age at diagnosis is approximately 25–30 years, and a significant proportion of patients are under 20. This pattern, sometimes called a slow-growing sarcoma of young adults, is one of the reasons ASPS is easily missed: a painless lump in a healthy young person's thigh is more often assumed to be a benign cyst or lipoma than a malignancy. For a broader look at how this cancer behaves in this age group, the page on sarcoma in adolescents & young adults (AYA) provides important context.

Symptoms, Imaging & How ASPS Is Diagnosed

The presenting symptoms of alveolar soft part sarcoma are dominated by what is not there: in the great majority of cases, the mass is painless. A slow-growing, deep, firm or rubbery swelling is the most common finding, and many patients report noticing it for one to three years before seeking medical attention. Occasionally, a first symptom is a neurological complaint — a headache, visual disturbance, or limb weakness — arising from a brain metastasis that develops before the primary tumour is found.

MRI — The Essential Imaging Investigation

MRI is the primary tool for evaluating the primary tumour in ASPS. On MRI, ASPS shows characteristic signal voids within and around the lesion, corresponding to the large, dilated vascular channels that run through the tumour. These "flow voids" on T1 and T2 images are a hallmark of ASPS and can raise the suspicion of this specific diagnosis before biopsy. MRI also defines the tumour's exact anatomical relationships — critical for surgical margin planning and for limb-sparing decision-making.

CT Chest — Mandatory at Diagnosis

Given ASPS's propensity for lung metastasis, a CT scan of the chest is mandatory at the time of diagnosis, not optional. Pulmonary metastases from ASPS may be too small to detect on a chest X-ray yet clearly visible on CT. Brain MRI is also recommended in patients with neurological symptoms and is increasingly used as part of staging in all newly diagnosed ASPS patients, given the high rate of brain involvement.

Core Needle Biopsy & Molecular Confirmation

Histological diagnosis requires a core needle biopsy, which must be planned in coordination with the operating surgeon so that the needle track can be included within the subsequent wide excision margin. The pathologist will stain for PAS-positive crystalline inclusions and perform immunohistochemistry showing TFE3 overexpression. Molecular confirmation of the ASPSCR1–TFE3 fusion by FISH (fluorescence in situ hybridisation) or next-generation sequencing is strongly recommended, because TFE3 expression alone can be seen in other tumours. An accurate molecular diagnosis is the gateway to appropriate treatment — including access to targeted therapy clinical trials.

How Alveolar Soft Part Sarcoma Is Treated

Treatment for ASPS is built around three realities: the tumour is chemotherapy-resistant, it is highly vascular and angiogenesis-dependent, and it can be clinically indolent for years even in the presence of metastases. The therapeutic approach therefore differs significantly from standard sarcoma protocols, and the choice of treatment is ideally made at a specialist sarcoma tumour board that has experience with this specific subtype. For a general overview of how systemic sarcoma therapy is delivered, the page on targeted therapy for sarcoma provides important background.

1. Surgery — Wide Local Excision of the Primary Tumour

For localised ASPS, surgical removal with clear (R0) margins remains the foundation of curative-intent treatment. ASPS is typically large and deep by the time of diagnosis, and achieving a clear margin requires careful pre-operative planning: MRI-based margin mapping, core needle biopsy with a track planned for excision, and a limb-sparing approach wherever feasible. Even in the presence of pulmonary metastases that are few in number and resectable, aggressive surgery on both the primary and the metastases is associated with the best outcomes — ASPS grows slowly enough that prolonged disease control is possible. Sarcoma treatment in Hyderabad at CION integrates surgical oncology, radiation, and medical oncology in the same plan.

2. Targeted Anti-Angiogenic Therapy

Because the ASPSCR1–TFE3 fusion drives robust angiogenesis — abnormal blood vessel formation — ASPS is exquisitely sensitive to drugs that block this pathway. The tyrosine kinase inhibitors sunitinib and cediranib have both demonstrated objective response rates of approximately 35–55% in metastatic ASPS in clinical trials, far exceeding the 5–10% seen with conventional doxorubicin-based chemotherapy. Pazopanib is a registered option for advanced sarcoma in India and is used when sunitinib is not available or tolerated. These agents are taken as oral tablets and are generally well tolerated in the young patients who make up most of the ASPS population, though blood pressure monitoring, thyroid function checks, and wound healing assessment are required during therapy.

3. Immunotherapy — Emerging Evidence

ASPS has an unusually high tumour immune infiltrate relative to other sarcomas, which has driven interest in immune checkpoint inhibitors. Early-phase trials with pembrolizumab (anti-PD-1) have shown meaningful responses in ASPS, including durable partial responses in patients with metastatic disease. Combination strategies — anti-PD-1 plus anti-VEGF — are under active investigation and represent the frontier of systemic therapy for this disease. At CION, eligibility for clinical trials and access to pembrolizumab are discussed at the tumour board for eligible patients.

4. Managing Brain Metastases

Brain metastases from ASPS are more common than in any other sarcoma subtype. When metastases are few (oligometastatic) and technically accessible, stereotactic radiosurgery (SRS) — a high-precision, non-invasive brain irradiation — is used to control individual lesions without whole-brain radiation. Surgical resection of a dominant brain metastasis is considered when the lesion is large and causing neurological symptoms. Whole-brain radiation is reserved for widespread metastases unamenable to focal treatment. Systemic targeted therapy is continued alongside local brain treatment whenever possible.

Prognosis — What to Expect With ASPS

ASPS is defined by a paradox: it is one of the most slowly progressive sarcomas, yet it is also one of the most prone to distant spread. For localised disease treated with wide excision, 5-year survival rates exceed 80%. When metastases are present at diagnosis, the disease can remain indolent — with patients surviving many years even with lung nodules that are present but not rapidly growing. The 10-year survival with metastatic ASPS was historically around 20–30%, but newer data from targeted therapy and immunotherapy trials suggest this is improving.

Several factors influence prognosis:

• Stage at diagnosis — localised disease has dramatically better outcomes than metastatic
• Tumour size and completeness of resection — clear surgical margins remain the strongest determinant of local control
• Age — younger patients (under 25) tend to have slower-progressing disease and better tolerance of systemic therapy
• Site of metastasis — brain metastases carry a worse prognosis than lung-only disease
• Response to targeted therapy — patients who respond to sunitinib or cediranib maintain disease control for a median of 12–19 months in trial data

Why Choose CION for Alveolar Soft Part Sarcoma?

ASPS is too rare to be managed well without a team that has seen it before. CION's multidisciplinary sarcoma programme brings together surgical oncology, medical oncology, radiation oncology, and dedicated sarcoma pathology under one roof, across Hyderabad.

Rare Sarcoma, Specialist Care — Across Hyderabad

Alveolar soft part sarcoma is rare enough that the right team makes all the difference. If you have a biopsy report, an MRI, or simply a lump that has been growing in a young person — talk to CION's sarcoma specialists before making any treatment decisions.